Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health…
Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera® (zanidatamab) to Treat Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that the European Commission (EC) has granted…
WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™…
BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has officially completed the acquisition of Inozyme Pharma, Inc. (Nasdaq: INZY), a move…
Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer…
argenx Advances ARGX-119 into Registrational Study for Congenital Myasthenic Syndromes Following Positive Phase 1b Data argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for…
Biogen Launches Global Phase 3 PROMINENT Trial Evaluating Felzartamab in Primary Membranous Nephropathy Biogen Inc. (Nasdaq: BIIB) has announced the initiation of dosing in its global Phase 3 clinical trial,…
Takeda Secures FDA Approval for GAMMAGARD LIQUID ERC, the First Ready-to-Use Liquid Immunoglobulin Therapy with Low IgA Content Takeda (TSE:4502/NYSE:TAK) announced today that the U.S. Food and Drug Administration (FDA)…
Merck Finalizes $3.4 Billion Acquisition of SpringWorks Therapeutics to Strengthen Rare Tumor Portfolio and Drive Sustainable Healthcare Growth Merck, a global leader in science and technology, today announced the successful…
Vertex Gains EU Approval for ALYFTREK®, a Next-Generation CFTR Modulator for Cystic Fibrosis Patients Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission has granted marketing authorization for ALYFTREK®…
Riliprubart Receives Orphan Drug Designation in Japan for Chronic Inflammatory Demyelinating Polyneuropathy Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart,…
Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer, Marking Milestone in Targeted Therapy Amgen (NASDAQ:AMGN) has announced a significant breakthrough in the treatment of gastric and…